血清白细胞介素-10水平在评估乳腺癌患者新辅助化疗疗效中作用

Role of serum interleukin-10 in evaluating the effect of neoadjuvant chemotherapy on breast cancer

目的探讨血清白细胞介素-10(interleukin-10,IL-10)水平评估乳腺癌患者新辅助化疗疗效的临床价值。方法接受FEC(氟尿嘧啶+表柔比星+环磷酰胺)新辅助化疗方案的乳腺癌患者40例为乳腺癌组,根据化疗疗效分为有效组24例和无效组16例。40例体检健康者为对照组。采用ELISA法检测乳腺癌组化疗前、后及对照组血清IL-10水平,并进行比较。绘制ROC曲线,评估乳腺癌患者化疗前IL-10水平预测新辅助化疗疗效的效能。结果乳腺癌组患者化疗前IL-10水平[(382.52±68.03)ng/L]明显高于对照组[(125.75±32.11)ng/L](P<0.05);乳腺癌组患者化疗后IL-10水平[(510.10±120.80)ng/L)高于化疗前(P<0.05);化疗前、后有效组患者IL-10水平[(381.70±36.80)、(426.83±39.72)ng/L]均低于无效组[(383.75±99.77)、(637.50±84.35)ng/L](P<0.05);乳腺癌患者化疗前IL-10水平预测新辅助化疗疗效的最佳截断值为370.04ng/L时,AUC为0.708(95%CI:0.534~0.883,P<0.001),灵敏度为75%,特异度为75%。结论血清IL-10水平对乳腺癌患者新辅助化疗疗效评估具有一定价值,降低血清IL-10水平有可能增加新辅助化疗的疗效。

Objective To explore the clinical value of serum interleukin-10(IL-10) level to evaluating the effect of neoadjuvant chemotherapy on breast cancer. Methods Forty breast cancer patients receiving FEC neoadjuvant chemotherapy were divided into effective group(n=24) and ineffective group(n=16), and another 40 healthy volunteers were as controls(control group). The level of serum IL-10 was detected by ELISA and compared before and after chemotherapy in breast cancer patients and with control group. The ROC curve was drawn to evaluate the predicting value of IL-10 on the effect of neoadjuvant chemotherapy in patients with breast cancer. Results The level of IL-10 was significantly higher in patients with breast cancer((382.52±68.03) ng/L) before chemotherapy than that in control group((125.75±32.11) ng/L)(P<0.01), and higher in breast cancer patients after chemotherapy((510.10±120.80) ng/L) than that before chemotherapy(P<0.05). The levels of IL-10 both before and after chemotherapy were significantly lower in effective group((381.70±36.80),(426.83±39.72) ng/L) than those in ineffective group((383.75±99.77),(637.50±84.35) ng/L)(P<0.05). When the optimal cut-off value of IL-10 was 370.04 ng/L, the AUC for predicting the effect of chemotherapy before treatment was 0.708(95%CI: 0.534-0.883, P<0.001), the sensitivity was 75%, and the specificity was 75%. Conclusion Serum IL-10 level has a clinical value to evaluating the effect of neoadjuvant chemotherapy on breast cancer, and the decreased IL-10 level may increase the effect of neoadjuvant chemotherapy.